Treatment outcomes for people with chronic inflammatory demyelinating polyneuropathy (CIDP)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an ambispective, observational, non‑interventional project that follows people in the United States with a neurologist‑confirmed CIDP diagnosis and ongoing impairment after standard therapy. Participants must have used at least one listed CIDP therapy for three months or longer and show residual disability (I-RODS score ≤44) at enrollment. Enrollment continues for about one year and each participant is followed for between one and two years through the end of study. The project collects real-world clinical information from records and follow-up visits without changing patients' prescribed treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

* Neurologist-confirmed diagnosis of CIDP found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed
* Active use of at least one of the following CIDP treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment

  * immunoglobulin
  * corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day
  * plasma exchange
  * efgartigimod alfa
  * azathioprine
  * mycophenolate mofetil
  * cyclosporine
  * rituximab
  * methotrexate
* Signed informed consent
* Residual impairment, disability, or neurological deficits at enrollment, as defined by a raw I-RODS score of 44 or below

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

* Evidence of participation in any interventional clinical trial with an investigational drug at the time of enrollment
* Hyperreflexia (increased reflexes) recorded in the medical record during a neurological exam the year before enrollment and after CIDP diagnosis
* Aged under 18 at the time of enrollment

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it's running

• Investigational Site
  Swiftwater, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
• Email: contact-us@sanofi.com
• Phone: 800-633-1610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Rilzabrutinib in adults with severe kidney impairment vs. normal kidney function

  This study tests how rilzabrutinib behaves in the body and its safety in adults with severe kidney impairment compared to healthy adults.

  Recruiting Phase 1 Sanofi · Hialeah, Florida · NCT07853131

• Duvakitug in adults with moderate to severe hidradenitis suppurativa

  This study tests different doses of duvakitug to see if it helps adults with moderate to severe hidradenitis suppurativa compared with placebo.

  Recruiting at 4 sites Phase 2 Sanofi · Birmingham, Alabama and 3 other locations · NCT07812116

• RSV+HMPV protein shot for adults 60 and older

  A single shot of a two-virus vaccine is being tested in adults 60+ to see if it can prevent RSV and hMPV infections compared with placebo.

  Recruiting at 21 sites Phase 2 Sanofi · Bruse, Australian Capital Territory and 20 other locations · NCT07810010

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.